Dr Gershenson was the only gynaecological cancer specialist acknowledged in this year’s award which highlights his expertise and contribution to the field. He has dedicated the award to all of his low-grade serous cancer patients and families. His research has influenced the treatments of low-grade serous cancer patients around the world.
A Phase 2 study of 15 women with low-grade serous ovarian cancer reported by investigators from the University of Texas MD Anderson Cancer Center found an “unprecedented response rate” with … Read More
“I’m pleased that we are living in times where progress is being made, and trials are being done because previously there weren’t trials specifically for low-grade serous cancer.” – Dr … Read More
Dr Susana Banerjee recently presented the updated results of the Verastem Phase 1/2 clinical trial (Frame study) at this years’s ESMO (the European Society for Medical Oncology) Congress. The results … Read More
“I’ve ended up seeing quite a lot of low-grade serious ovarian cancer patients. I find it an intriguing disease. We still don’t know as much as we should but we’re … Read More
One of the difficulties with low-grade serous ovarian cancer is that a lack of data and research can make it difficult for doctors to know what is the most appropriate … Read More
Below is a list of some of our favourite low-grade serous ovarian cancer women with blogs and social media accounts. They are just a few examples of the many wonderful … Read More
In 2019 Cure Our Ovarian Cancer was privileged to sit down with world renowned low-grade serous expert Dr Gersheson from The University of Texas MD Anderson Cancer Center. In Part … Read More